PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
Pepaxto Withdrawn from US Market Following OCEAN Trial Results
The phase 3 OCEAN study evaluated Pepaxto in combination with low-dose dexamethasone in adults with relapsed or refractory multiple myeloma following 2 to 4 lines of prior therapy and who were refractory to lenalidomide in the last line of therapy.
Acalabrutinib, Venetoclax, Obinutuzumab Shows Promise as Frontline Therapy for Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib, venetoclax, and obinutuzumab would be a helpful option for frontline treatment of CLL.
MRD Assessment Can Guide Treatment Discontinuation in CLL/SLL
Stopping treatment after induction did not impact disease-free survival in patients with undetectable minimal residual disease.
Diagnosis and Management of Differentiation Syndrome in Patients With Acute Myeloid Leukemia
Differentiation syndrome is a potentially severe complication in AML, although prompt management is usually effective and rarely requires cessation of targeted therapy.
Genomic Markers May Predict Clinical Outcomes in Patients With B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether genomic evaluation in patients with BCR-ABL1 negative B-ALL may improve risk assessments.
Tafasitamab Plus Lenalidomide and Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma
The primary outcome measure is progression-free survival.
Trial Comparing Pirtobrutinib With Bendamustine Plus Rituximab in CLL/SLL
The study’s primary outcome is progression-free survival by independent review.
FDA Approves Lenalidomide Capsules in 2.5mg, 20mg Strengths
The company also received tentative approval for the 5mg, 10mg, 15mg, and 25mg strengths.
Trial to Compare Diets in Patients With Leukemia or MDS and Prolonged Neutropenia
The trial’s primary objective is to compare the incidence of major infections.
Phase 3 Trial Comparing Rituximab Biosimilar and Originator in Follicular Lymphoma
The primary outcome measure is overall response rate.
Younger Age at Diagnosis May Predict Higher VTE Risk in Patients With Multiple Myeloma
Researchers sought to determine whether higher-intensity thromboprophylaxis may be necessary for reducing the risk of VTE in younger patients with multiple myeloma.
Breast, Prostate Cancer Common in Patients With COVID-19 and Cancer History
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
Risk of Cytokine Release Syndrome After CAR T-Cell Therapy May Vary by Ethnicity
Hispanic patients had significantly higher rates of severe cytokine release syndrome.
Salvage Autologous Stem Cell Transplantation May Improve Outcomes for Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether salvage therapy with high-dose chemotherapy followed by ASCT would improve survival in patients with MM.
Utilization Patterns Explain Nonadherence to Treatment for Multiple Myeloma, CML, Some Metastatic Cancers
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
Patients With B-Cell Non-Hodgkin Lymphoma Treated With Anti-CD20 Antibodies Have Impaired Response to COVID-19 Vaccine
Researchers sought to determine whether patients with B-NHL who had treatment with anti-CD20 antibodies had an impaired serological response to an mRNA COVID-19 vaccine.
Poor Prognosis Seen for Patients With B-Cell Acute Lymphoblastic Leukemia Progression After CAR-T Therapy
Researchers sought to determine whether patients with B-ALL who progress after CAR-T therapy would have a poor prognosis.
Autologous HSCT Provides Long-Term Survival Benefit in Mantle Cell Lymphoma
Transplant improved progression-free and overall survival at a median follow-up of 14 years.
Brentuximab Vedotin Provides ‘Robust Clinical Benefit’ in Cutaneous T-Cell Lymphoma
Time to next treatment was significantly longer with brentuximab vedotin.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
Loading... 
Loading...